FDA reviewers spotlighting the first two drugs in a new class of cholesterol-lowering therapies to be considered by its advisors this week suggested that each injectable medicine provides benefits, but also expressed concerns about which patients might benefit most and what side effects patients taking the new drugs may encounter.